About: Strategy of oral immunization: significance for systemic and mucosal immunity and use for prevention and therapy

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Strategy of oral immunization: significance for systemic and mucosal immunity and use for prevention and therapy Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Projekt, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	http://linked.opendata.cz/ontology/domain/vavai/Projekt
rdfs:seeAlso	http://www.isvav.cz/projectDetail.do?rowId=VS96149
Description	Possibilities of modulation of mucosal and systemic immunity after oral immunization will be studied. The effect of various adjuvants, carriers and vectors on induction of protective immunity or oral tolerance will be tested. Bacillus firmus has strong immunomodulatory activities and will be used as adjuvant and antigen carrier. A mutant of E. coli O83 K24 H31 hlyA- with excellent intestine colonizing properties will be used as live vector for tetanic toxin. Effectiveness of adenylate-cyclase toxin (ACT) of Bordetella pertussis as a constituent of subunit vaccine against pertussis will be followed. Integration of various heterologous epitopes into ACT can influence their presentation to lymphocytes and character of immune response. Chimeric ACT with gliadin epitopes will be exploited in the study of antigen presentation and its significance for pathogeny of celiac disease. The results expected could be used (en) Budou sledovány možnosti ovlivnění systémové a slizniční imunity po orální imunizaci. Bude testován účinek různých adjuvancií, nosičů a vektorů: Bacillus firmus jako adjuvans a nosič (ervent. vektor), mutanta Escherichia coli 083 K24 H31 hlyA- jako živý vektor, adenylát-cyklázový é mechanismy uplatňující se při patogeneze celiakie. Výsledky mohou být využitelné pro rozvoj nových vakcinačních strategií.
Title	Strategy of oral immunization: significance for systemic and mucosal immunity and use for prevention and therapy (en) Strategie orální imunizace, její výzkum pro systémovou a slizniční imunitu a využití k preventivním a léčebným účelům
skos:notation	VS96149
http://linked.open...avai/cep/aktivita	Strengthening of research at the universities
http://linked.open...kovaStatniPodpora	http://linked.opendata.cz/resource/domain/vavai/projekt/VS96149/celkovaStatniPodpora
http://linked.open...ep/celkoveNaklady	http://linked.opendata.cz/resource/domain/vavai/projekt/VS96149/celkoveNaklady
http://linked.open...ep/duvernostUdaju	S - Úplné a pravdivé údaje nepodléhající ochraně podle zvláštních právních předpisů
http://linked.open.../cep/fazeProjektu	600254
http://linked.open...ai/cep/hlavniObor	EA - Morfologické obory a cytologie
http://linked.open...hodnoceniProjektu	U - Uspěl podle zadání, tj. byly splněny cíle a jeho předpokládané výsledky uvedené ve smlouvě / rozhodnutí o poskytnutí podpory
http://linked.open.../cep/klicovaSlova	mucosal immunity; peroral immunization; oral tolerance; mucosal adjuvants; antigen carriers; mucosal (en)
http://linked.open...ep/partnetrHlavni	1. lékařská fakulta
http://linked.open...inujicichPrijemcu	0 (xsd:int)
http://linked.open...cep/pocetPrijemcu	1 (xsd:int)
http://linked.open...ocetSpoluPrijemcu	0 (xsd:int)
http://linked.open.../pocetVysledkuRIV	23 (xsd:int)
http://linked.open...enychVysledkuVRIV	23 (xsd:int)
http://linked.open...iciPoslednihoRoku	2001
http://linked.open...atUdajeProjZameru	2001
http://linked.open...usZobrazovaneFaze	DUU
http://linked.open...ai/cep/typPojektu	P - Projekt výzkumu a vývoje financovaný ze státního rozpočtu
http://linked.open.../cep/vedlejsiObor	EE - Mikrobiologie, virologie FO - Dermatovenerologie
http://linked.open...jektu+dodavatelem	Nové pracoviště je zaměřeno na stidium slizniční imunologie, slizniční vakcinace a vztahu bakterií a hostitele.Byly získány nové poznatky o imunomodulačních vlastnostech B. firmus a adenylát-cyklázového toxinu B. pertussis a o patogeneze celiakie. (cs)
http://linked.open...tniCyklusProjektu	ZBBBKU
http://linked.open.../cep/klicoveSlovo	mucosal immunity oral tolerance antigen carriers mucosal adjuvants peroral immunization
is http://linked.open...vavai/riv/projekt of	Enhanced systemic and mucosal antibody responses to a model protein antigen after intranasal and intratracheal immunisation using Bacillus firmus as an adjuvantn Effector mechanisms in intestinal immunity and inflammation. Effector mechanisms in intestinal immunity and inflammation. Malignancy in coeliac disease and dermatitis herpetiformis. Increased levels of circulating ICAM-1, E-selectin, and IL-2 receptors in celiac disease. Induction of a polarized Th1 response by insertion of multiple copies of a viral T-cell epitope into adenylate cyclase of Bordetella pertussis. Malignancy in coeliac disease and dermatitis herpetiformis. Bacterial adjuvant and carrier for mucosal immunization with a protein antigen Acylation of lysine 983 is sufficient for toxin activity of Bordetella pertussis adenylate cyclase. Mucosal immunozation via respiratory tract Stimulation of macrophages by Bacillus firmus: production of nitric oxide and cytokines. An amphipathic alpha-helix including glutamates 509 and 516 is crucial for membrane translocation of adenylate cyclase toxin and modulates formation and cation selectivity of its membrane channels. Identification of common epitopes on gliadin, enterocytes, and calreticulin recognised by antigliadin antibodies of patients with coeliac disease. In vitro immunoglobulin response of fetal B-cells is influenced by perinatal infections and antibiotic treatment: a study in preterm infants. Immunopathogenetic mechanisms of coeliac disease. In vivo induction of CTL responses by recombinant adenylate cyclase of Bordetella pertussis carrying multiple copies of a viral CD8+ T-cell epitope. Role of immunosuppressive therapy in refractory sprue-like disease. Delivery of CD8+ T-cell epitopes into major histocompatibility complex class I antigen presentation pathway by Bordetella pertussis adenylate cyclase:delineation of cell invasive structures and permissive insertion sites. Detection of ICAM-1 in experimentally induced colitis of ICAM-1-deficient and wild-type mice: an immunohistochemical study. Intercellular adhesion molecule-1 (ICAM-1) deficiency protects mice against severe forms of experimentally induced colitis. Oral administration of antigens from intestinal flora anaerobic bacteria reduces the severity of experimental acute colitis in BALB/c mice. Occurrence of IgA and IgG autoantibodies to calreticulin in coeliac disease and various autoimmune diseases. Delivery of multiple epitopes by recombinant detoxified adenylate cyclase of Bordetella pertussis induces protective antiviral immunity.
is http://linked.open...vavai/cep/projekt of	http://linked.opendata.cz/resource/domain/vavai/cep/ucast/VS96149/1996/ico%3A61388971 http://linked.opendata.cz/resource/domain/vavai/cep/ucast/VS96149/1996/orjk%3A11110 http://linked.opendata.cz/resource/domain/vavai/cep/ucast/VS96149/1997/ico%3A61388971 http://linked.opendata.cz/resource/domain/vavai/cep/ucast/VS96149/1997/orjk%3A11110 http://linked.opendata.cz/resource/domain/vavai/cep/ucast/VS96149/1998/ico%3A00216208 http://linked.opendata.cz/resource/domain/vavai/cep/ucast/VS96149/1999/orjk%3A11110 http://linked.opendata.cz/resource/domain/vavai/cep/ucast/VS96149/2000/orjk%3A11110 http://linked.opendata.cz/resource/domain/vavai/cep/ucast/VS96149/2001/orjk%3A11110

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 39 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software